ISRG Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

Price

$443.73

Market Cap

$201.11B

P/E (TTM)

72.0

EPS (TTM)

$7.87

Revenue (TTM)

$10.06B

Div Yield

—

ROE

16.7%

Debt/Equity

—

52W Range

$418 – $604

ISRG Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

10-Year Performance Revenue, net income, margins and EPS trends

Revenue & Net Income $10.06B

2016-12-31 → 2025-12-31

EPS $7.87

2016-12-31 → 2025-12-31

Free Cash Flow $2.49B

2016-12-31 → 2025-12-31

Margins 28.4%

2016-12-31 → 2025-12-31

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric

5Y trend

ISRG

Peer Median

P/E (TTM)

72.0

15.7

P/S (TTM)

20.0

23.9

P/B

11.3

3.4

Price / FCF

80.7

—

Profitability Gross, operating and net margins; ROE, ROA, ROIC

Metric

5Y trend

ISRG

Peer Median

Gross Margin

66.0%

47.4%

Operating Margin

29.3%

—

Net Profit Margin

28.4%

-509.8%

ROA

14.6%

-25.4%

ROE

16.7%

-39.7%

ROIC

14.4%

—

Financial Health Debt, liquidity, solvency — balance sheet strength

Metric

5Y trend

ISRG

Peer Median

Current Ratio

4.9

4.6

Quick Ratio

3.7

—

Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR

Metric

5Y trend

ISRG

Peer Median

Revenue YoY

20.5%

—

Revenue CAGR 3Y

17.4%

—

Revenue CAGR 5Y

18.2%

—

EPS YoY

22.6%

—

Net Income YoY

23.0%

—

Per Share Metrics EPS, book value per share, cash flow per share, dividend per share

Metric

5Y trend

ISRG

Peer Median

EPS (Diluted)

$7.87

—

Capital Efficiency Asset turnover, inventory turnover, receivables turnover

Metric

5Y trend

ISRG

Peer Median

ISRG Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

BUY 41 analysts

Strong Buy 11 26.8%
Buy 18 43.9%
Hold 11 26.8%
Sell 1 2.4%
Strong Sell 0 0.0%

12-Month Price Target

30 analysts · 2026-05-18

Median $580.00

Now $443.73

Low $378.00

High $750.00

Median target $580.00 +30.7%

Mean target $577.01 +30.0%

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

Avg Surprise

0.25%

Period	EPS Actual	EPS Est	Surprise
March 31, 2026	$2.50	$2.14	0.36%
Dec. 31, 2025	$2.53	$2.30	0.23%
Sept. 30, 2025	$2.40	$2.02	0.38%
June 30, 2025	$2.19	$1.96	0.23%
March 31, 2025	$1.81	$1.76	0.05%

Peer Comparison Key metrics vs sector peers

Ticker	Market Cap	P/E	Rev YoY	Net Margin	ROE	Gross Margin
ISRG	$201.11B	72.0	20.5%	28.4%	16.7%	66.0%
ABT	$250.18B	33.7	5.7%	14.7%	13.1%	—
SYK	$134.44B	41.8	11.2%	12.9%	15.1%	64.0%
BSX	—	49.1	19.9%	14.4%	12.6%	69.0%
EW	$49.50B	46.6	11.6%	17.7%	10.6%	78.0%
IDXX	$53.93B	51.7	10.4%	24.6%	69.2%	61.8%
BDX	—	25.3	8.2%	7.7%	6.5%	—
RMD	$37.77B	27.1	9.8%	27.2%	25.0%	59.4%
GEHC	—	18.0	4.8%	10.1%	22.1%	40.0%
DXCM	$25.54B	31.8	15.6%	17.9%	31.4%	60.1%
ZBH	$28.66B	25.3	7.2%	8.6%	5.6%	—

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

Income Statement 16

Annual Income Statement data for ISRG
Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue	$10.06B	$8.35B	$7.12B	$6.22B	$5.71B	$4.36B	$4.48B	$3.72B	$3.14B	$2.71B	$2.38B	$2.13B
Cost of Revenue	$3.42B	$2.72B	$2.39B	$2.03B	$1.75B	$1.50B	$1.37B	$1.12B	$936M	$814M	$806M	$718M
Gross Profit	$6.64B	$5.63B	$4.73B	$4.20B	$3.96B	$2.86B	$3.11B	$2.60B	$2.20B	$1.89B	$1.58B	$1.41B
R&D Expense	$1.31B	$1.15B	$999M	$879M	$671M	$595M	$557M	$418M	$329M	$240M	$197M	$178M
SG&A Expense	$2.38B	$2.14B	$1.96B	$1.74B	$1.47B	$1.22B	$1.18B	$987M	$810M	$704M	$640M	$691M
Operating Expenses	$3.70B	$3.29B	$2.96B	$2.62B	$2.14B	$1.81B	$1.74B	$1.40B	$1.14B	$943M	$838M	$869M
Operating Income	$2.95B	$2.35B	$1.77B	$1.58B	$1.82B	$1.05B	$1.37B	$1.20B	$1.06B	$950M	$740M	$545M
Other Non-op	$366M	$325M	$192M	$30M	$69M	$157M	$128M	$80M	$42M	$36M	$18M	$4M
Pretax Income	$3.31B	$2.67B	$1.96B	$1.61B	$1.89B	$1.21B	$1.50B	$1.28B	$1.10B	$985M	$758M	$549M
Income Tax	$435M	$336M	$142M	$262M	$162M	$140M	$120M	$154M	$434M	$247M	$170M	$130M
Net Income	$2.86B	$2.32B	$1.80B	$1.32B	$1.70B	$1.06B	$1.38B	$1.13B	$671M	$738M	$589M	$419M
EPS (Basic)	$8.00	$6.54	$5.12	$3.72	$4.79	$3.02	$3.98	$9.92	$6.01	$6.43	$5.29	$11.35
EPS (Diluted)	$7.87	$6.42	$5.03	$3.65	$4.66	$2.94	$3.85	$9.49	$5.77	$6.26	$5.18	$11.11
Shares (Basic)	356,900,000	355,200,000	351,200,000	355,700,000	356,100,000	351,100,000	346,200,000	113,700,000	111,700,000	114,900,000	111,300,000	36,900,000
Shares (Diluted)	362,700,000	362,000,000	357,400,000	362,000,000	365,800,000	361,000,000	358,400,000	118,800,000	116,300,000	117,900,000	113,700,000	37,700,000
EBITDA	$2.95B	$2.35B	$1.77B	$1.58B	$1.82B	$1.05B	$1.37B	$1.20B	$1.05B	$945M	$740M	$545M

Balance Sheet 24

Annual Balance Sheet data for ISRG
Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Cash & Equivalents	$3.37B	$2.03B	$2.75B	$1.58B	$1.29B	$1.62B	$1.17B	$858M	$648M	$1.04B	$715M	$600M
Short-term Investments	$2.57B	$1.99B	$2.47B	$2.54B	$2.91B	$3.49B	$2.05B	$2.21B	$1.31B	$1.52B	$845M	$632M
Receivables	$1.53B	$1.23B	$1.13B	$942M	$783M	$646M	$645M	$682M	$508M	$430M	$394M	$315M
Inventory	$1.84B	$1.49B	$1.22B	$893M	$587M	$602M	$596M	$409M	$241M	$182M	$168M	$182M
Prepaid Expense	$477M	$385M	$314M	$300M	$271M	$268M	$200M	$179M	$99M	$83M	$74M	$83M
Current Assets	$9.78B	$7.11B	$7.89B	$6.25B	$5.84B	$6.63B	$4.66B	$4.33B	$2.81B	$3.25B	$2.20B	$1.81B
PP&E (Net)	$5.34B	$4.65B	$3.54B	$2.37B	$1.88B	$1.58B	$1.27B	$812M	$613M	$458M	$432M	$387M
PP&E (Gross)	$7.62B	$6.53B	$5.10B	$3.61B	$2.85B	$2.33B	$1.84B	$1.25B	$960M	$780M	$699M	$610M
Accum. Depreciation	$2.28B	$1.88B	$1.56B	$1.24B	$969M	$758M	$563M	$436M	$347M	$322M	$267M	$223M
Goodwill	$370M	$348M	$349M	$348M	$344M	$337M	$307M	$241M	$201M	$201M	$201M	$198M
Intangibles	$17M	$23M	$39M	$50M	$70M	$77M	$112M	$67M	$26M	$32M	$50M	$74M
Total Assets	$20.46B	$18.74B	$15.44B	$12.97B	$13.55B	$11.17B	$9.73B	$7.85B	$5.78B	$6.49B	$4.91B	$3.96B
Accounts Payable	$255M	$193M	$189M	$147M	$121M	$82M	$124M	$101M	$82M	$68M	$53M	$62M
Accrued Liabilities	·	·	·	·	·	·	·	·	$170M	$151M	$96M	$127M
Current Liabilities	$2.01B	$1.75B	$1.66B	$1.42B	$1.15B	$965M	$1.03B	$821M	$663M	$596M	$492M	$501M
Capital Leases	$132M	$112M	$64M	$70M	$67M	$58M	$69M	·	·	·	·	·
Other Non-current Liabilities	·	·	·	·	·	·	·	·	$22M	$113M	$96M	$79M
Total Liabilities	$2.52B	$2.21B	$2.04B	$1.86B	$1.60B	$1.41B	$1.45B	$1.16B	$996M	$709M	$588M	$580M
Common Stock	$400.0K	$400.0K	$400.0K	$400.0K	$400.0K	$400.0K	$100.0K	$100.0K	$100.0K	$0	$0	$0
Retained Earnings	$7.01B	$6.80B	$4.74B	$3.50B	$4.76B	$3.26B	$2.49B	$1.52B	$115M	$1.57B	$899M	$488M
AOCI	$43M	$-51M	$-12M	$-162M	$-24M	$25M	$12M	$-13M	$-16M	$-9M	$-10M	$-5M
Stockholders' Equity	$17.82B	$16.43B	$13.31B	$11.04B	$11.90B	$9.73B	$8.26B	$6.68B	$4.78B	$5.78B	$4.32B	$3.38B
Liabilities + Equity	$20.46B	$18.74B	$15.44B	$12.97B	$13.55B	$11.17B	$9.73B	$7.85B	$5.78B	$6.49B	$4.91B	$3.96B
Shares Outstanding	355,100,000	356,600,000	352,300,000	350,000,000	357,700,000	353,100,000	347,900,000	343,400,000	112,300,000	38,800,000	37,400,000	36,600,000

Cash Flow 12

Annual Cash Flow data for ISRG
Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Stock-based Comp	$788M	$677M	$593M	$513M	$449M	$395M	$336M	$261M	$209M	$178M	$168M	$169M
Deferred Tax	$19M	$-135M	$-281M	$-185M	$-64M	$58M	$-6M	$34M	$60M	$21M	$5M	$-35M
Amort. of Intangibles	$13M	$17M	$20M	$28M	$27M	$50M	$43M	$14M	$13M	$18M	$24M	$22M
Operating Cash Flow	$3.03B	$2.42B	$1.81B	$1.49B	$2.09B	$1.48B	$1.60B	$1.17B	$1.14B	$1.09B	$806M	$665M
CapEx	$540M	$1.11B	$1.06B	$532M	$340M	$342M	$426M	$187M	$191M	$54M	$81M	$106M
Investing Cash Flow	$666M	$-3.27B	$-360M	$1.37B	$-2.46B	$-941M	$-1.15B	$-1.05B	$379M	$-1.28B	$-850M	$-154M
Stock Repurchased	$2.30B	$0	$416M	$2.61B	$0	$134M	$270M	$0	$2.27B	$42M	$184M	$1.00B
Net Stock Activity	$-2.30B	$0	$-416M	$-2.61B	$0	$-134M	$-270M	$0	$-2.27B	$-42M	$-184M	$-1.00B
Financing Cash Flow	$-2.36B	$151M	$-288M	$-2.57B	$43M	$-86M	$-168M	$126M	$-1.91B	$514M	$159M	$-692M
Net Change in Cash	$1.34B	$-708M	$1.17B	$295M	$-332M	$456M	$273M	$246M	$-388M	$322M	$114M	$-182M
Taxes Paid	$538M	·	·	·	·	·	·	·	·	·	·	·
Free Cash Flow	$2.49B	$1.30B	$750M	$958M	$1.74B	$1.14B	$1.17B	$982M	$953M	$989M	$691M	$560M

Profitability 8

Annual Profitability data for ISRG
Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Gross Margin	66.0%	67.5%	66.4%	67.4%	69.3%	65.6%	69.5%	69.9%	70.1%	69.9%	66.2%	66.3%
Operating Margin	29.3%	28.1%	24.8%	25.4%	31.9%	24.1%	30.7%	32.2%	33.7%	34.9%	31.0%	25.6%
Net Margin	28.4%	27.8%	25.2%	21.2%	29.8%	24.3%	30.8%	30.3%	21.1%	27.2%	24.7%	19.7%
Pretax Margin	32.9%	32.0%	27.5%	25.8%	33.1%	27.7%	33.5%	34.4%	35.0%	36.3%	31.8%	25.8%
EBITDA Margin	29.3%	28.1%	24.8%	25.4%	31.9%	24.1%	30.7%	32.2%	33.7%	34.9%	31.0%	25.6%
ROA	14.6%	13.6%	12.7%	10.0%	13.8%	10.2%	15.7%	16.6%	10.8%	12.9%	13.3%	10.6%
ROE	16.7%	15.6%	14.8%	11.5%	15.8%	11.8%	18.5%	19.7%	12.6%	14.6%	15.3%	12.2%
ROIC	14.4%	12.5%	12.3%	11.9%	14.0%	9.5%	15.3%	15.8%	13.4%	12.3%	13.3%	12.3%

Liquidity & Solvency 2

Annual Liquidity & Solvency data for ISRG
Metric	Trend	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Current Ratio		4.9	4.1	4.8	4.4	5.1	6.9	4.5	5.3	4.0	5.4	4.5	3.7
Quick Ratio		3.7	3.0	3.8	3.6	4.3	6.0	3.8	4.6	3.5	5.0	4.0	3.1

Efficiency 3

Annual Efficiency data for ISRG
Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Asset Turnover	0.5	0.5	0.5	0.5	0.5	0.4	0.5	0.5	0.5	0.5	0.5	0.5
Inventory Turnover	2.1	2.0	2.3	2.7	2.9	2.5	2.7	3.4	4.4	4.7	4.6	4.0
Receivables Turnover	7.3	7.1	6.9	7.2	8.0	6.8	6.7	6.3	6.6	6.6	6.7	6.9

Per Share 5

Annual Per Share data for ISRG
Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Book Value / Share	$50.19	$46.08	$37.77	$31.55	$33.27	$82.68	$71.24	$58.33	$42.08	$148.91	$115.49	$92.33
Revenue / Share	$27.75	$23.07	$19.93	$17.19	$15.61	$36.23	$37.48	$31.35	$26.90	$68.81	$62.91	$56.54
Cash Flow / Share	$8.36	$6.67	$5.08	$4.12	$5.71	$12.34	$13.37	$9.85	$9.84	$26.54	$20.37	$17.64
Cash / Share	$9.48	$5.69	$7.81	$4.52	$3.61	$13.79	$10.07	$7.49	$5.77	$26.72	$19.11	$16.40
EPS (TTM)	$7.87	$6.42	$5.03	$3.65	$4.66	$2.94	$3.85	$9.49	$5.77	$6.26	$5.18	$11.11

Growth Rates 9

Annual Growth Rates data for ISRG
Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue YoY	20.5%	17.2%	14.5%	9.0%	31.0%	·	·	·	·	·	·	·
Revenue CAGR 3Y	17.4%	13.5%	17.8%	·	·	·	·	·	·	·	·	·
Revenue CAGR 5Y	18.2%	·	·	·	·	·	·	·	·	·	·	·
EPS YoY	22.6%	27.6%	37.8%	-21.7%	58.5%	·	·	·	·	·	·	·
EPS CAGR 3Y	29.2%	11.3%	19.6%	·	·	·	·	·	·	·	·	·
EPS CAGR 5Y	21.8%	·	·	·	·	·	·	·	·	·	·	·
Net Income YoY	23.0%	29.2%	36.0%	-22.4%	60.7%	·	·	·	·	·	·	·
Net Income CAGR 3Y	29.3%	10.9%	19.2%	·	·	·	·	·	·	·	·	·
Net Income CAGR 5Y	21.9%	·	·	·	·	·	·	·	·	·	·	·

Valuation (TTM) 10

Annual Valuation (TTM) data for ISRG
Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue TTM	$10.06B	$8.35B	$7.12B	$6.22B	$5.71B	$4.36B	$4.48B	$3.72B	$3.14B	$2.71B	$2.38B	$2.13B
Net Income TTM	$2.86B	$2.32B	$1.80B	$1.32B	$1.70B	$1.06B	$1.38B	$1.13B	$671M	$738M	$589M	$419M
Market Cap	$201.11B	$186.13B	$118.85B	$92.87B	$128.52B	$32.10B	$22.86B	$18.28B	$13.66B	$2.73B	$2.27B	$2.15B
P/E	72.0	81.3	67.1	72.7	77.1	92.8	51.2	16.8	21.1	11.3	11.7	5.3
P/S	20.0	22.3	16.7	14.9	22.5	7.4	5.1	4.9	4.4	1.0	1.0	1.0
P/B	11.3	11.3	8.9	8.4	10.8	3.3	2.8	2.7	2.9	0.5	0.5	0.6
P / Tangible Book	11.5	11.6	9.2	8.7	11.2	3.4	·	·	·	·	·	·
P / Cash Flow	66.4	77.1	65.5	62.3	61.5	21.6	14.3	15.6	11.9	2.6	2.9	3.2
P / FCF	80.7	142.8	158.6	96.9	74.0	28.1	19.5	18.6	14.3	2.8	3.3	3.8
Earnings Yield	1.4%	1.2%	1.5%	1.4%	1.3%	1.1%	1.9%	5.9%	4.7%	8.9%	8.5%	18.9%

Income Statement 16

Quarterly Income Statement data for ISRG
Metric	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022
Revenue	$2.77B	$2.87B	$2.51B	$2.44B	$2.25B	$2.41B	$2.04B	$2.01B	$1.89B	$1.93B	$1.74B	$1.76B	$1.70B	$1.66B	$1.56B	$1.52B
Cost of Revenue	$940M	$962M	$843M	$822M	$796M	$771M	$664M	$637M	$645M	$651M	$576M	$584M	$583M	$544M	$505M	$499M
Gross Profit	$1.83B	$1.90B	$1.66B	$1.62B	$1.46B	$1.64B	$1.37B	$1.37B	$1.25B	$1.28B	$1.17B	$1.17B	$1.11B	$1.11B	$1.05B	$1.02B
R&D Expense	$362M	$353M	$329M	$313M	$316M	$295M	$286M	$280M	$284M	$260M	$249M	$244M	$245M	$244M	$217M	$207M
SG&A Expense	$613M	$687M	$573M	$561M	$563M	$613M	$511M	$525M	$492M	$567M	$452M	$464M	$480M	$494M	$436M	$418M
Operating Expenses	$975M	$1.04B	$903M	$874M	$880M	$907M	$797M	$805M	$776M	$827M	$701M	$709M	$725M	$738M	$653M	$626M
Operating Income	$855M	$864M	$760M	$743M	$578M	$735M	$577M	$567M	$469M	$450M	$466M	$463M	$388M	$372M	$399M	$398M
Other Non-op	$85M	$91M	$96M	$89M	$90M	$75M	$94M	$87M	$69M	$66M	$56M	$36M	$34M	$22M	$4M	$9M
Pretax Income	$940M	$956M	$855M	$832M	$668M	$810M	$671M	$654M	$538M	$516M	$522M	$499M	$422M	$395M	$403M	$407M
Income Tax	$114M	$156M	$146M	$168M	$-35M	$122M	$100M	$123M	$-9M	$-95M	$102M	$73M	$61M	$58M	$78M	$93M
Net Income	$822M	$795M	$704M	$658M	$698M	$686M	$565M	$527M	$545M	$606M	$416M	$421M	$355M	$325M	$324M	$308M
EPS (Basic)	$2.31	$2.23	$1.98	$1.84	$1.95	$1.93	$1.59	$1.48	$1.54	$1.73	$1.18	$1.20	$1.01	$0.93	$0.91	$0.86
EPS (Diluted)	$2.28	$2.19	$1.95	$1.81	$1.92	$1.89	$1.56	$1.46	$1.51	$1.69	$1.16	$1.18	$1.00	$0.90	$0.90	$0.85
Shares (Basic)	354,900,000	-715,700,000	356,600,000	358,500,000	357,500,000	-709,100,000	355,800,000	355,000,000	353,500,000	-701,600,000	351,700,000	350,900,000	350,200,000	-716,100,000	355,300,000	358,100,000
Shares (Diluted)	359,800,000	-727,800,000	361,800,000	364,100,000	364,600,000	-722,200,000	362,700,000	361,000,000	360,500,000	-714,100,000	358,200,000	357,300,000	356,000,000	-729,100,000	360,500,000	363,900,000
EBITDA	$855M	·	$760M	$743M	$578M	·	$577M	$567M	$469M	·	$466M	$463M	$388M	·	$399M	$398M

Balance Sheet 22

Quarterly Balance Sheet data for ISRG
Metric	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022
Cash & Equivalents	$2.01B	$3.37B	$2.81B	$3.40B	$2.57B	$2.03B	$2.41B	$3.04B	$2.84B	·	$3.60B	$3.44B	$2.14B	·	$1.54B	$1.54B
Short-term Investments	$2.51B	$2.57B	$2.10B	$1.92B	$1.94B	$1.99B	$1.82B	$1.72B	$1.96B	·	$2.87B	$2.36B	$2.55B	·	$2.78B	$2.90B
Receivables	$1.60B	$1.53B	$1.26B	$1.27B	$1.22B	$1.23B	$1.15B	$1.11B	$1.13B	·	$963M	$904M	$925M	·	$850M	$838M
Inventory	$1.95B	$1.84B	$1.78B	$1.67B	$1.55B	$1.49B	$1.48B	$1.38B	$1.30B	·	$1.15B	$1.01B	$947M	·	$837M	$724M
Prepaid Expense	$752M	$477M	$575M	$483M	$371M	$385M	$349M	$404M	$405M	·	$317M	$323M	$313M	·	$292M	$293M
Current Assets	$8.81B	$9.78B	$8.53B	$8.75B	$7.66B	$7.11B	$7.22B	$7.65B	$7.63B	·	$8.90B	$8.03B	$6.88B	·	$6.29B	$6.29B
PP&E (Net)	$5.45B	$5.34B	$5.15B	$4.99B	$4.80B	$4.65B	$4.43B	$4.12B	$3.80B	·	$3.08B	$2.83B	$2.58B	·	$2.24B	$2.11B
PP&E (Gross)	·	$7.62B	·	·	·	$6.53B	$6.24B	·	·	·	$4.55B	·	·	·	·	·
Accum. Depreciation	·	$2.28B	·	·	·	$1.88B	$1.81B	·	·	·	$1.47B	·	·	·	·	·
Goodwill	$613M	$370M	$348M	$349M	$348M	$348M	$348M	$348M	$348M	$349M	$348M	$349M	$349M	$348M	$348M	$349M
Intangibles	$174M	$17M	$14M	$18M	$20M	$23M	$25M	$29M	$34M	·	$42M	$47M	$45M	·	$57M	$66M
Total Assets	$20.11B	$20.46B	$19.35B	$20.16B	$19.22B	$18.74B	$17.74B	$16.65B	$15.83B	·	$14.71B	$13.90B	$13.05B	·	$13.26B	$13.71B
Accounts Payable	$333M	$255M	$291M	$267M	$276M	$193M	$219M	$194M	$194M	·	$196M	$200M	$164M	·	$164M	$150M
Current Liabilities	$1.91B	$2.01B	$1.80B	$1.69B	$1.54B	$1.75B	$1.68B	$1.49B	$1.38B	·	$1.68B	$1.54B	$1.31B	·	$1.23B	$1.18B
Capital Leases	·	$132M	·	·	·	$112M	·	·	·	·	·	·	·	·	·	·
Total Liabilities	$2.51B	$2.52B	$2.31B	$2.21B	$2.01B	$2.21B	$2.07B	$1.85B	$1.78B	·	$2.09B	$1.94B	$1.76B	·	$1.69B	$1.62B
Common Stock	$400.0K	$400.0K	$400.0K	$400.0K	$400.0K	$400.0K	$400.0K	$400.0K	$400.0K	·	$400.0K	$400.0K	$400.0K	·	$400.0K	$400.0K
Retained Earnings	$6.40B	$7.01B	$6.42B	$7.61B	$7.14B	$6.80B	$6.13B	$5.58B	$5.07B	·	$4.21B	$3.81B	$3.40B	·	$4.02B	$4.68B
AOCI	$16M	$43M	$26M	$3M	$-27M	$-51M	$13M	$-24M	$-9M	·	$-56M	$-80M	$-108M	·	$-188M	$-144M
Stockholders' Equity	$17.47B	$17.82B	$16.93B	$17.85B	$17.11B	$16.43B	$15.58B	$14.71B	$13.96B	·	$12.54B	$11.88B	$11.22B	·	$11.52B	$12.02B
Liabilities + Equity	$20.11B	$20.46B	$19.35B	$20.16B	$19.22B	$18.74B	$17.74B	$16.65B	$15.83B	·	$14.71B	$13.90B	$13.05B	·	$13.26B	$13.71B
Shares Outstanding	354,400,000	355,100,000	354,900,000	358,400,000	358,400,000	356,600,000	356,200,000	355,300,000	354,700,000	352,300,000	352,000,000	351,300,000	350,400,000	350,000,000	353,300,000	357,100,000

Cash Flow 11

Quarterly Cash Flow data for ISRG
Metric	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022
Stock-based Comp	$210M	$203M	$204M	$196M	$185M	$177M	$173M	$174M	$153M	$150M	$156M	$146M	$140M	$128M	$138M	$127M
Amort. of Intangibles	$7M	$3M	$3M	$3M	$3M	$3M	$4M	$5M	$5M	$5M	$5M	$5M	$5M	$8M	$8M	$6M
Operating Cash Flow	$912M	$892M	$841M	$715M	$582M	$823M	$706M	$620M	$265M	$228M	$548M	$666M	$371M	$438M	$383M	$447M
CapEx	$103M	$162M	$105M	$155M	$117M	$312M	$248M	$309M	$242M	$436M	$256M	$178M	$194M	$139M	$168M	$129M
Investing Cash Flow	$-914M	$-209M	$401M	$261M	$214M	$-1.26B	$-1.41B	$-467M	$-128M	$-1.04B	$-447M	$558M	$573M	$575M	$544M	$466M
Stock Repurchased	$1.12B	$201M	$1.91B	$181M	$0	$0	$0	$0	$0	$66M	$0	$0	$350M	$1.00B	$1.00B	$500M
Net Stock Activity	$-1.12B	·	·	·	·	·	·	·	$0	·	·	·	$-350M	·	·	·
Dividends Paid	·	·	$0	·	·	·	$0	·	·	·	$0	·	·	·	·	·
Financing Cash Flow	$-1.35B	$-138M	$-1.84B	$-148M	$-236M	$49M	$98M	$50M	$-47M	$-32M	$62M	$63M	$-381M	$-964M	$-927M	$-482M
Net Change in Cash	$-1.36B	$558M	$-597M	$829M	$555M	$-384M	$-620M	$200M	$97M	$-853M	$165M	$1.29B	$565M	$47M	$3M	$433M
Free Cash Flow	$809M	·	·	·	$465M	·	·	·	$24M	·	·	·	$177M	·	·	·

Profitability 8

Quarterly Profitability data for ISRG
Metric	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022
Gross Margin	66.1%	·	66.4%	66.3%	64.7%	·	67.4%	68.3%	65.9%	·	66.9%	66.7%	65.6%	·	67.5%	67.2%
Operating Margin	30.9%	·	30.3%	30.5%	25.7%	·	28.3%	28.2%	24.8%	·	26.7%	26.4%	22.9%	·	25.6%	26.1%
Net Margin	29.6%	·	28.1%	27.0%	31.0%	·	27.7%	26.2%	28.8%	·	23.8%	24.0%	20.9%	·	20.8%	20.2%
Pretax Margin	33.9%	·	34.1%	34.1%	29.7%	·	32.9%	32.6%	28.5%	·	29.9%	28.4%	24.9%	·	25.9%	26.7%
EBITDA Margin	30.9%	·	30.3%	30.5%	25.7%	·	28.3%	28.2%	24.8%	·	26.7%	26.4%	22.9%	·	25.6%	26.1%
ROA	4.2%	·	3.8%	3.6%	4.0%	·	3.5%	3.5%	3.8%	·	3.0%	3.0%	2.7%	·	2.5%	2.4%
ROE	4.8%	·	4.3%	4.0%	4.5%	·	4.0%	4.0%	4.3%	·	3.5%	3.5%	3.0%	·	2.8%	2.7%
ROIC	4.3%	·	3.7%	3.3%	3.6%	·	3.1%	3.1%	3.4%	·	3.0%	3.3%	3.0%	·	2.8%	2.5%

Liquidity & Solvency 2

Quarterly Liquidity & Solvency data for ISRG
Metric	Trend	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022
Current Ratio		4.6	·	4.7	5.2	5.0	·	4.3	5.1	5.6	·	5.3	5.2	5.3	·	5.1	5.4
Quick Ratio		3.2	·	3.4	3.9	3.7	·	3.2	3.9	4.3	·	4.4	4.4	4.3	·	4.2	4.5

Efficiency 3

Quarterly Efficiency data for ISRG
Metric	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022
Asset Turnover	0.1	·	0.1	0.1	0.1	·	0.1	0.1	0.1	·	0.1	0.1	0.1	·	0.1	0.1
Inventory Turnover	0.5	·	0.5	0.5	0.6	·	0.5	0.5	0.6	·	0.6	0.7	0.7	·	0.7	0.8
Receivables Turnover	2.0	·	2.1	2.1	1.9	·	1.9	2.0	1.8	·	1.9	2.0	1.9	·	2.0	2.0

Per Share 5

Quarterly Per Share data for ISRG
Metric	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022
Book Value / Share	$49.31	·	$47.70	$49.79	$47.73	·	$43.75	$41.40	$39.36	·	$35.62	$33.81	$32.01	·	$32.59	$33.67
Revenue / Share	$7.70	·	$6.92	$6.70	$6.18	·	$5.62	$5.57	$5.24	·	$4.87	$4.91	$4.76	·	$4.32	$4.18
Cash Flow / Share	$2.53	·	·	·	$1.60	·	·	·	$0.74	·	·	·	$1.04	·	·	·
Cash / Share	$5.66	·	$7.91	$9.50	$7.18	·	$6.78	$8.55	$8.01	·	$10.23	$9.78	$6.12	·	$4.35	$4.30
EPS (TTM)	$7.96	·	$7.24	$6.75	$6.45	·	$5.69	$5.31	$4.85	·	$4.24	$3.93	$3.75	·	$3.78	$3.92

Valuation (TTM) 10

Quarterly Valuation (TTM) data for ISRG
Metric	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022
Revenue TTM	$9.97B	·	$9.24B	$8.74B	$8.19B	·	$7.68B	$7.40B	$7.09B	·	$6.75B	$6.53B	$6.26B	·	$6.12B	$5.96B
Net Income TTM	$2.88B	·	$2.63B	$2.45B	$2.34B	·	$2.05B	$1.91B	$1.74B	·	$1.52B	$1.41B	$1.35B	·	$1.38B	$1.43B
Market Cap	$163.37B	·	$158.72B	$194.76B	$177.50B	·	$174.99B	$158.06B	$141.56B	·	$102.89B	$120.12B	$89.52B	·	$66.22B	$71.67B
P/E	57.9	·	61.8	80.5	76.8	·	86.3	83.8	82.3	·	68.9	87.0	68.1	·	49.6	51.2
P/S	16.4	·	17.2	22.3	21.7	·	22.8	21.4	20.0	·	15.2	18.4	14.3	·	10.8	12.0
P/B	9.3	·	9.4	10.9	10.4	·	11.2	10.7	10.1	·	8.2	10.1	8.0	·	5.8	6.0
P / Tangible Book	9.8	·	9.6	11.1	10.6	·	11.5	11.0	10.4	·	8.5	10.5	8.3	·	6.0	6.2
P / Cash Flow	179.2	·	·	·	305.2	·	·	·	533.4	·	·	·	241.0	·	·	·
P / FCF	202.0	·	·	·	381.7	·	·	·	6023.7	·	·	·	504.9	·	·	·
Earnings Yield	1.7%	·	1.6%	1.2%	1.3%	·	1.2%	1.2%	1.2%	·	1.5%	1.1%	1.5%	·	2.0%	1.9%

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue	$10.06B	$8.35B	$7.12B	$6.22B	$5.71B
Gross Margin %	66.0%	67.5%	66.4%	67.4%	69.3%
Operating Margin %	29.3%	28.1%	24.8%	25.4%	31.9%
Net Income	$2.86B	$2.32B	$1.80B	$1.32B	$1.70B
Diluted EPS	$7.87	$6.42	$5.03	$3.65	$4.66

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Current Ratio	4.9	4.1	4.8	4.4	5.1
Quick Ratio	3.7	3.0	3.8	3.6	4.3

Cash Flow

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Free Cash Flow	$2.49B	$1.30B	$750M	$958M	$1.74B

ISRG AI Analyst Panel — Bullish and Bearish Views 2026Q2 debate: Claude, Grok, Gemini, ChatGPT on the stock's prospects

Round 1 — Opening Takes

Grok NEUTRAL 0.75

↑ Bullish

I see the strongest bull case for ISRG as its razor-and-blade model fueling endless profits from a growing installed base of da Vinci systems worldwide. The 28.58% net margin means Intuitive converts nearly a third of sales straight to bottom-line profit, far above peers, thanks to recurring instrument revenue. Debt-to-equity sits at 0.0, giving the company a rock-solid balance sheet to fund R&D without leverage risk. EPS TTM has climbed to 7.56, up from 7.17 last quarter, signaling procedure volume acceleration into 2026.

↓ Bearish

The bear case breaks if robotic surgery hype fades amid competition or reimbursement cuts, exposing that sky-high valuation. P/E TTM at 73x towers over peers like SYK's 40x, meaning the market prices in perfection with no room for growth slowdowns. Recent price action shows a sharp drop to $512 close after touching $545, with volume spiking to 8.6 million shares, hinting at profit-taking. ETF outflows including ISRG signal institutional caution.

Claude NEUTRAL 0.68

↑ Bullish

Intuitive Surgical owns the surgical robotics market with near-monopoly economics and a moat that's only widening. The company is printing cash with zero debt, a 66% gross margin, and a 29% net margin that most medical device peers can't touch. Yes, the stock trades at 73 times trailing earnings — well above peers like Stryker at 40x or Abbott at 26x — but that multiple reflects a business that converts 16% of shareholder equity into profit year after year while growing installed base faster than competitors can react. The installed base compounds, procedure volume follows, and pricing power stays intact.

↓ Bearish

This valuation leaves almost no room for disappointment, and robotics adoption curves flatten eventually. At 73x earnings, ISRG is pricing in flawless execution for years — any miss on procedure growth, margin compression from competition, or slower international expansion triggers a sharp multiple contraction. The current ratio dropped from 5.6 to 4.97 in one quarter, signaling cash burn or capital deployment that warrants watching. Peers like Stryker and Zimmer are investing heavily in competing platforms; if adoption slows or pricing pressure emerges, ISRG's premium multiple has nowhere to hide.

Gemini NEUTRAL 0.80

↑ Bullish

Intuitive Surgical dominates the robotic surgery market with an unassailable competitive moat that allows for massive, recurring profitability. The company maintains a gross margin of 66.38%. This indicates that for every dollar of revenue, they retain over sixty-six cents after direct production costs, reflecting immense pricing power in the medical device space. Furthermore, with a debt-to-equity ratio of zero, they operate with a pristine balance sheet. This means the company is entirely self-funded and faces no interest rate risk, providing the financial flexibility to aggressively reinvest in their next-generation surgical platforms while competitors struggle with leverage.

↓ Bearish

The valuation has simply become too detached from the underlying growth trajectory to justify a new position at these levels. Investors are currently paying a P/E ratio of 73.09. This implies the market expects near-perfect execution for years to come, leaving absolutely no room for even minor earnings misses or clinical setbacks. Additionally, the P/S ratio sits at 20.89. This high multiple means the stock is priced for hyper-growth that is increasingly difficult to sustain as they reach market saturation, making the current share price highly vulnerable to a multiple compression if growth rates normalize toward industry averages.

Chatgpt NEUTRAL 0.62

↑ Bullish

I think ISRG's edge lies in a durable robotic platform and a high-margin service ecosystem. ROE TTM: 16.06%. That level signals ISRG uses equity efficiently and can sustain earnings growth. Gross margin TTM: 66.38%. That margin suggests pricing power and strong fixed-cost absorption in their device ecosystem. Debt/Equity: 0.0. A debt-free balance sheet gives optionality to fund R&D, expansion, or buybacks.

↓ Bearish

I think ISRG is richly priced relative to growth risk, which could unwind. P/E TTM: 73.0905. That lofty multiple prices in aggressive growth unless the growth trajectory stays flawless. P/S TTM: 20.8877. A high sales multiple means the stock relies on top-line expansion for returns; any slowdown hits multiple. P/B (annual): 11.3128. A double-digit price-to-book suggests over-optimism about asset-like value; if profitability stalls, the stock could revert.

Round 2 — Responses & Rebuttals

Grok

Claude, your point about the current ratio dropping from 5.6 to 4.97 signaling cash burn overlooks the balance sheet strength. At 4.97, it still means short-term assets cover liabilities nearly five times over, giving ISRG ample liquidity to fund da Vinci expansions or R&D without strain. With debt-to-equity at zero, this dip likely reflects smart capital deployment, not distress.

Claude

I think Grok is reading the price action wrong. Yes, we saw a drop to $512 and volume spike to 8.6 million, but that happened in early July after the stock had already run from $508 to $544 in the prior three weeks. That's not profit-taking on a trend — that's normal weekly chop in a $200 billion stock. The real tell is EPS climbing to 7.56 from 7.17 quarter-over-quarter. That 5% beat matters because it shows procedure volume is actually accelerating, not stalling. ETF flows are noise compared to earnings momentum.

Gemini ⇄ Mind changed

Grok, your point about the institutional caution signaled by recent ETF outflows is a critical piece of the puzzle that I overlooked in my initial assessment. When you look at the volume spike to 8.6 million shares during the recent pullback, it suggests that the smart money is actively rebalancing away from this premium valuation. That volume represents a significant shift in ownership dynamics. If institutional support wanes, the stock's 73 times earnings multiple becomes extremely fragile, as there are fewer buyers left to justify such an aggressive price for a medical device company.

Chatgpt

Claude, your moat argument is compelling, but a 73x trailing P/E leaves ISRG vulnerable if growth or margins slow. That level implies the market expects years of flawless execution, so even a modest miss in procedure volumes or pricing power could trigger meaningful multiple compression. I value the debt-free stance and strong margins, but valuation discipline matters here — capital deployment flexibility won't save the stock if the growth path stalls.

Round 3 — Final Rebuttals

G

Grok

Claude, I push back on dismissing ETF flows as noise — they signal real institutional caution worth heeding. The March 25 news flagged notable outflows from ETFs including ISRG, right as volume spiked to 8.6 million shares on the drop to $512 close. That surge is well above the prior week's 5.4 million average, pointing to distribution by big holders, not random chop. At 73x earnings, this trim makes sense if procedure growth moderates, amplifying downside risk.

C

Claude

I want to push back on something nobody's challenged yet: Gemini, you said institutional support waning makes the 73x multiple fragile, but you're reading the ETF outflow as smart money rebalancing away. I'd flip that. A $200 billion surgical robotics monopoly with 66% gross margins and zero debt doesn't get sold by institutions because of valuation — it gets trimmed for portfolio rebalancing or sector rotation. The real risk isn't that institutions lose faith; it's that procedure growth actually does slow as the installed base matures. EPS climbed 5% quarter-over-quarter, but I need to see if that's from volume or just pricing. If international adoption is already plateauing and U.S. procedures are normalizing post-pandemic, then 73x earnings isn't fragile because of flows — it's fragile because the growth narrative itself is cracking. That's the bear case worth taking seriously.

G

Gemini

I want to challenge Claude’s dismissal of institutional flows. Claude, you called ETF outflows noise, but when you look at the recent 8.6 million share volume spike, you are ignoring the technical reality of how large-cap stocks rotate. Institutional investors are currently shifting capital toward value-oriented healthcare plays as the interest rate cycle stabilizes. This rotation out of high-multiple growth names is a real macro headwind for Intuitive. Even with a perfect balance sheet, the stock is trading at 73 times earnings, which is a valuation that requires constant, heavy institutional buying to maintain momentum.

C

Chatgpt

Claude, your moat claim is compelling, but the valuation is a major guardrail. The stock trades at a trailing P/E of 73x. That means the market is pricing in flawless execution for years, leaving little cushion for any step back in procedure growth or pricing power. Even with a dominant installed base, any hiccup could trigger meaningful multiple compression. If regulatory or reimbursement headwinds arise, the premium is particularly vulnerable.

Price Forecasts

Model	3M Target	6M Target	Reasoning
G Grok	3M Target $525.00	6M Target $545.00	Reasoning I think ISRG's da Vinci monopoly drives modest upside as procedure growth sustains premium pricing power amid watchful institutions. The key catalyst is the Q2 2026 earnings release in late July, where EPS beating 7.56 on 15%+ procedure volume accelerates the bull case. One big risk is a Stryker robotics platform gaining FDA clearance, eroding the moat narrative. My 6-month $545 target implies a 72x P/E on current EPS, meaning the market still bets on 16% ROE fueling expansion without leverage, but any slowdown caps it there.
C Claude	3M Target $520.00	6M Target $545.00	Reasoning My thesis: ISRG's moat is real, but the 73x P/E multiple is the constraint, not the installed base. The stock re-rates on proof that procedure volume growth is holding, not decelerating. Catalyst: 2026Q2 earnings in late July will show whether the 5% EPS beat from Q1 reflects durable volume acceleration or one-quarter noise. If procedure volumes stay above 8% year-over-year growth, the multiple holds and the stock drifts toward $545 by year-end. Risk: international adoption plateaus faster than expected, forcing management to guide down procedure growth, triggering 15–20% multiple compression to 60x earnings. At 73x, the market is pricing in flawless execution with zero margin for error. Current price $514.59 leaves room for modest upside if execution holds, but downside is asymmetric if growth cracks.
G Gemini	3M Target $505.00	6M Target $485.00	Reasoning My thesis is that the stock will face a period of multiple contraction as investors rotate out of high-premium growth stocks into more defensive healthcare names. The primary catalyst for a downside move will be the next earnings report, where any deceleration in procedure volume growth will force analysts to slash their lofty expectations. Conversely, the biggest risk to my bearish outlook is a major breakthrough in international market penetration that reignites top-line acceleration. Intuitive currently trades at a P/E of 73.09. This extreme multiple means the market is paying for years of flawless future performance, leaving the share price highly susceptible to even minor disappointments in quarterly execution.
C Chatgpt	3M Target $525.00	6M Target $550.00	Reasoning I think ISRG can drift higher in the near term, but the lofty valuation will cap upside. The key catalyst is the upcoming quarterly earnings print showing continued da Vinci procedure growth and stable margins. The risk is slower-than-expected adoption or reimbursement headwinds that could curb growth and invite multiple compression. The P/E 73 implies the market is pricing near-perfect execution; a miss would trigger meaningful multiple compression. That said, the balance sheet strength and high gross margins provide a buffer if the cycle turns.

Latest News Recent headlines mentioning this company

Intuitive Surgical (ISRG) Is Among The Best Agentic AI Stocks To Buy Right Now Yahoo Finance · 4 days, 21 hours ago
Noteworthy Monday Option Activity: LLY, ISRG, LULU Nasdaq · 1 week, 2 days ago
Better Than Intuitive Surgical? 1 Under-the-Radar Healthcare Stock to Buy and Hold Forever Nasdaq · 1 week, 5 days ago
The Real Reason Intuitive Surgical Keeps Winning: A Cash Machine Hiding in Plain Sight Nasdaq · 2 weeks, 4 days ago
Market Update: BRO, ISRG, PG, SANM, KMI Yahoo Finance · 3 weeks, 1 day ago
Intuitive Surgical Q1 results top estimates as robotic surgery demand accelerates Yahoo Finance · 3 weeks, 5 days ago
Why Intuitive Surgical Stock Soared Today Nasdaq · 4 weeks ago
Intuitive Surgical Inc. Bottom Line Rises In Q1 Nasdaq · 4 weeks, 1 day ago
Mizuho, BTIG, and Evercore Cut Intuitive Surgical (ISRG) Price Targets Yahoo Finance · 4 weeks, 1 day ago
August 21st Options Now Available For Intuitive Surgical (ISRG) Nasdaq · 1 month, 1 week ago

Trading Signals Recent buy/sell signals with entry price and risk/reward ratio

My Metrics Your personal watchlist — selected rows from Full Fundamentals

📊

Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

ISRG Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

ISRG Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

Moving averages & overlays

Volume

Oscillators

Momentum & trend

10-Year Performance Revenue, net income, margins and EPS trends

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Profitability Gross, operating and net margins; ROE, ROA, ROIC

Financial Health Debt, liquidity, solvency — balance sheet strength

Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR

Per Share Metrics EPS, book value per share, cash flow per share, dividend per share

Capital Efficiency Asset turnover, inventory turnover, receivables turnover

ISRG Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

12-Month Price Target

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

Peer Comparison Key metrics vs sector peers

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

ISRG AI Analyst Panel — Bullish and Bearish Views 2026Q2 debate: Claude, Grok, Gemini, ChatGPT on the stock's prospects

Round 1 — Opening Takes

Round 2 — Responses & Rebuttals

Round 3 — Final Rebuttals

Price Forecasts

Latest News Recent headlines mentioning this company

Trading Signals Recent buy/sell signals with entry price and risk/reward ratio

My Metrics Your personal watchlist — selected rows from Full Fundamentals